According to the latest report by IMARC Group, titled “Recombinant DNA Technology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the market to grow at a CAGR of XX% during 2021-2026.
The introduction of recombinant DNA technology, or genetic engineering, involves altering genetic material outside an organism and obtaining enhanced and desired characteristics in living organisms. It includes the insertion of DNA fragments from several sources with a desirable gene sequence through an appropriate vector. Besides this, recombinant DNA technology aids in the safe, affordable, and sufficient production of vital proteins needed for dietary purposes and fighting health problems. Consequently, it has multidisciplinary applications and a remarkable potential to improve health, food resources, resistance to divergent adverse environmental effects, etc.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Global Recombinant DNA Technology Market Trends:
Recombinant DNA technology is being increasingly utilized for treating different health conditions, primarily by developing new vaccines and pharma products. This, along with the improving treatment strategies due to the developing diagnostics kits, monitoring devices, new therapeutic approaches, etc., are among the significant factors fueling the market. Moreover, the rising number of research activities conducted on genetically modified organisms (GMO), which include microorganisms considered as bio degraders and clean fuel producers, is also propelling the market for recombinant DNA technology. Additionally, the escalating integration of recombinant DNA technology with effective gene therapy for replacing defective genes with normal ones is further anticipated to stimulate the market growth in the coming years.
Request Free Sample Report: https://www.imarcgroup.com/recombinant-dna-technology-market/requestsample
Global Recombinant DNA Technology Market 2021-2026 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Amgen Inc, Cibus, F.Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline plc., Horizon Discovery Group plc, Merck KGaA, New England Biolabs, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A and Syngene International Ltd (Biocon Limited).
The report has segmented the market on the basis on region, disc type, material type and end user.
Breakup by Product:
Medical
o Therapeutic Agent
o Human Protein
o Vaccines
Non-Medical
o Biotech Crops
o Specialty Chemicals
o Others
Breakup by Component:
Expression System
Cloning Vector
Breakup by Application:
Food and Agriculture
Health and Disease
Environment
Others
Breakup by End User:
· Biotechnology and Pharmaceutical Companies
· Academic and Government Research Institutes
· Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/recombinant-dna-technology-market
Key highlights of the report:
Market Performance (2015-2020)
Market Outlook (2021-2026)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
If you want latest primary and secondary data (2021-2026) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Related Report by IMARC Group:
Latin America Telehealth Market Report: https://www.imarcgroup.com/latin-america-telehealth-market
Europe CBD Oil Market Report: https://www.imarcgroup.com/europe-cbd-oil-market
India Organ Preservation Market Report: https://www.imarcgroup.com/india-organ-preservation-market
India Generic Injectables Market Report: https://www.imarcgroup.com/india-generic-injectables-market
United States Transfection Technologies Market Report: https://www.imarcgroup.com/united-states-transfection-technologies-market
Veterinary Infectious Disease Diagnostics Market Report: https://www.imarcgroup.com/veterinary-infectious-disease-diagnostics-market
Premenstrual Syndrome Treatment Market Report: https://www.imarcgroup.com/premenstrual-syndrome-treatment-market
Drug Abuse Testing Market Report: https://www.imarcgroup.com/drug-abuse-testing-market
Protein Purification and Isolation Market Report: https://www.imarcgroup.com/protein-purification-isolation-market
United States Insulin Pumps Market Report: https://www.imarcgroup.com/united-states-insulin-pumps-market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800